PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue69,4298,67644,377
Cost of Revenue---
Gross Profit69,4298,67644,377
Operating Expenses
Research Development37,56928,19628,592
Selling General and Administrative18,75619,7849,739
Non Recurring--2,676
Total Operating Expenses---
Operating Income or Loss13,104-39,3043,370
Income from Continuing Operations
Total Other Income/Expenses Net-34-34-34
Earnings Before Interest and Taxes12,577-39,2523,421
Interest Expense---
Income Before Tax12,577-39,2523,421
Income Tax Expense1,844-133-989
Minority Interest-205205
Net Income From Continuing Ops10,806-39,1124,410
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income10,806-39,1124,410
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares10,806-39,1124,410